Intercept Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Intercept Pharmaceuticals, Inc.‘s stocks are currently a part of 142 hedge funds’ portfolios, which represents 78.99% of the total amount of its stocks outstanding. This makes up a total of 25.19M shares of Intercept Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -1.19% or -304.28K shares fewer. As for the holding position changes, 30.99% (44) of current hedge fund investors increased the number of shares held, 33.8% (48) of current holders sold a part of the shares held, and 14.79% (21) closed the holdings completely. 19 hedge funds are new holders of Intercept Pharmaceuticals, Inc. stock in Q1 2022, it is 13.38% of total holders.
Hedge funds holding Intercept Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 166 |
|---|---|
| Q3 2017 | 154 |
| Q4 2017 | 165 |
| Q1 2018 | 146 |
| Q2 2018 | 163 |
| Q3 2018 | 174 |
| Q4 2018 | 191 |
| Q1 2019 | 201 |
| Q2 2019 | 195 |
| Q3 2019 | 184 |
| Q4 2019 | 212 |
| Q1 2020 | 186 |
| Q2 2020 | 189 |
| Q3 2020 | 173 |
| Q4 2020 | 170 |
| Q1 2021 | 147 |
| Q2 2021 | 127 |
| Q3 2021 | 134 |
| Q4 2021 | 144 |
| Q1 2022 | 142 |
Hedge funds changes in Intercept Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 28 | 62 | 52 | 12 | 12 |
|---|---|---|---|---|---|
| Q3 2017 | 33 | 64 | 37 | 42 | -22 |
| Q4 2017 | 37 | 54 | 49 | 25 | 0 |
| Q1 2018 | 18 | 59 | 41 | 34 | -6 |
| Q2 2018 | 32 | 55 | 47 | 15 | 14 |
| Q3 2018 | 36 | 52 | 55 | 24 | 7 |
| Q4 2018 | 44 | 61 | 55 | 27 | 4 |
| Q1 2019 | 45 | 86 | 43 | 35 | -8 |
| Q2 2019 | 31 | 98 | 39 | 33 | -6 |
| Q3 2019 | 29 | 70 | 49 | 40 | -4 |
| Q4 2019 | 51 | 60 | 72 | 22 | 7 |
| Q1 2020 | 26 | 55 | 71 | 48 | -14 |
| Q2 2020 | 37 | 69 | 51 | 30 | 2 |
| Q3 2020 | 31 | 54 | 52 | 47 | -11 |
| Q4 2020 | 32 | 58 | 49 | 34 | -3 |
| Q1 2021 | 17 | 39 | 56 | 38 | -3 |
| Q2 2021 | 13 | 54 | 29 | 32 | -1 |
| Q3 2021 | 24 | 32 | 47 | 15 | 16 |
| Q4 2021 | 34 | 36 | 47 | 25 | 2 |
| Q1 2022 | 19 | 44 | 48 | 21 | 10 |
Hedge funds changes in Intercept Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 112,209,000 | 65,737,000 |
|---|---|---|
| Q3 2017 | 117,184,000 | 15,094,130,000 |
| Q4 2017 | 82,904,000 | 67,915,000 |
| Q1 2018 | 59,941,000 | 52,467,000 |
| Q2 2018 | 98,418,000 | 66,609,000 |
| Q3 2018 | 191,004,000 | 188,667,000 |
| Q4 2018 | 156,669,000 | 224,651,000 |
| Q1 2019 | 232,199,000 | 459,809,000 |
| Q2 2019 | 103,194,000 | 91,967,000 |
| Q3 2019 | 104,441,000 | 122,144,000 |
| Q4 2019 | 264,202,000 | 313,914,000 |
| Q1 2020 | 79,577,000 | 79,909,000 |
| Q2 2020 | 72,545,000 | 82,470,000 |
| Q3 2020 | 50,814,000 | 55,056,000 |
| Q4 2020 | 35,999,000 | 47,786,000 |
| Q1 2021 | 24,804,000 | 36,156,000 |
| Q2 2021 | 22,164,000 | 20,361,000 |
| Q3 2021 | 16,961,000 | 23,198,000 |
| Q4 2021 | 25,297,000 | 27,966,000 |
| Q1 2022 | 21,001,000 | 14,580,000 |